Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.
Lung Cancer
; 169: 67-76, 2022 07.
Article
in En
| MEDLINE
| ID: mdl-35660971
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Non-Small-Cell Lung
/
Lung Neoplasms
Limits:
Humans
Language:
En
Journal:
Lung Cancer
Journal subject:
NEOPLASIAS
Year:
2022
Document type:
Article
Country of publication: